BioTech IP Review

Assignee: Ionis Pharmaceuticals, Inc.
Patent Number: 12,297,431
Filing Date: (priority filing in 2022)
Patent Issued: May 13, 2025
Inventors: Gene Hang (et al.)

---

What It Covers

This patent protects compositions and methods for reducing the expression of the huntingtin (HTT) gene — the gene responsible for Huntington’s disease, a devastating inherited neurodegenerative disorder with no cure and limited treatment options.

• Antisense oligonucleotides (ASOs):
  The invention claims modified oligonucleotide compounds designed to bind specifically to huntingtin mRNA, causing its degradation or blocking its translation, thereby reducing mutant huntingtin protein levels.
• Methods of use:
  It covers methods of treating Huntington’s disease by administering these ASOs to patients, with the goal of slowing, halting, or reversing neurodegeneration linked to the toxic protein product of the HTT gene.
• Pharmaceutical compositions:
  Patented formulations include ASO sequences and modifications that improve stability, cellular uptake, and target specificity — key for clinical performance.

---

Why This Patent Is Important

1. High Unmet Medical Need

Huntington’s disease is a severe genetic condition characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. There are no disease-modifying therapies approved, making effective approaches highly valuable clinically and commercially.

2. Therapeutic Platform Value

Ionis is a leader in antisense technology — using ASOs to modulate gene expression — and this patent strengthens its IP position in neurological disease therapies, a strategic growth area beyond its metabolic and cardiovascular programs.

3. Broad Intellectual Property Protection

By securing explicit claims over huntingtin modulation, Ionis gains commercial exclusivity and leverage in licensing or co-development deals, especially if programs move toward clinical success or partner with larger biopharma firms.

4. Portfolio Synergy with Clinical Pipeline

This fits into Ionis’s broader pipeline of RNA-targeting medicines (e.g., FDA-approved Tryngolza for lipid disease and Donidalorsen for hereditary angioedema), showcasing the company’s transition to a commercial-stage biotech with diversified indications and revenue streams.

---

Summary

U.S. Patent No. 12,297,431 — issued May 13, 2025 to Ionis Pharmaceuticals — covers antisense oligonucleotide therapies that reduce huntingtin gene expression, a promising approach for treating Huntington’s disease. This patent is strategically important because it protects a gene-targeting technology in a high-value, high-unmet-need therapeutic area and strengthens Ionis’s leadership in RNA-based medicines.